Viatris names Scott Smith as new CEO

The board of directors of Pittsburgh-based Viatris Inc., a global healthcare company, recently named Scott A. Smith as the company’s next CEO, effective April 1.

Smith was appointed to lead the second phase of the company’s strategic plan, which begins next year. He is a current board member and previously served as president of BioAtla and as president and chief operating officer of Celgene Corp.

The board selected Smith because of his experience developing and executing regulatory, clinical, and business development strategies.

“I have personally been extremely impressed with his overall approach to leadership, deep industry knowledge, and forward-looking business mindset,” Robert J. Coury, Viatris executive chairman, said. “The board believes that the foundation is now firmly in place for Phase 2 of the company’s strategic plan, including the recent divestiture of our biologics business to Biocon Biologics as well as our other upcoming planned divestitures and the recent establishment of the Viatris Eye Care Division. ”

Current CEO Michael Goettler will work closely with Smith to ensure a smooth transition.

Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas. It employs approximately 37,000 people worldwide, with global centers in Pittsburgh, China, and India.